ValiRx PLC Shareholder Communications (2408W)
August 17 2022 - 2:00AM
UK Regulatory
TIDMVAL
RNS Number : 2408W
ValiRx PLC
17 August 2022
17 August 2022
ValiRx PLC ("ValiRx" or the "Company")
Shareholder Communications
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health is
pleased to announce the appointment of strategic marketing and PR
agency, V Formation Limited and the appointment of Dr Adam
Hargreaves as a shareholder representative. The appointments
represent the Company's continued strategy to improve and enhance
communications with its shareholders.
V Formation Limited is a Nottingham-based public relations and
marketing communications agency that specialises in supporting
clients in the life sciences sector, ensuring that news and
corporate development updates are optimised and communicated in a
clear, transparent and precise manner. V Formation will liaise
closely with Dr Hargreaves in his role as shareholder
representative, as well as with ValiRx's Nominated Adviser and
brokers, to improve the interpretation and dissemination of Company
newsflow following publication via a regulatory information
provider.
Dr Adam Hargreaves has agreed to become a shareholder
representative to help improve communications between the Company
and shareholders. The Company's overall policy on shareholder
communications is unchanged, with written quarterly updates and
quarterly live Q&A events continuing. However, shareholders can
additionally communicate with Dr Hargreaves directly to seek
clarification of any details that have been publicly announced, or
through a shareholder community. Dr Hargreaves will have regular
interaction with the Company to ensure that shareholders' views are
fully represented to the Board. Shareholders wishing to communicate
directly with Board members are welcome to do so, with a prompt
response when possible.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476
796496
Dr Suzanne Dilly, CEO www.valirx.com
Suzanne.Dilly@valirx.com
Dr Adam Hargreaves, Shareholder Representative
Adam.Hargreaves@pathcelerate.com
V Formation (Public Relations)
Contact details
Lucy Wharton - Senior PR Executive www.vformation.biz
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
+44 (0)115 787 0206
----------------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20
Adviser) 7213 088
Liam Murray/Jo Turner/Ludovico Lazzaretti
----------------------------------
Cenkos Securities Limited (Joint Broker) Tel: +44 (0) 20
7397 8900
Russell Kerr/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
----------------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20
James Pope / Andy Thacker 3657 0050
----------------------------------
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and
women's health to improve patient lives. We provide the scientific,
financial and commercial framework towards enabling rapid
translation of innovative science into clinical development.
With our extensive and proven experience in research and drug
development, we select and incubate promising novel drug candidates
and guide them through an optimised process of development, from
pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and
commercial domains, with the aim of achieving a more streamlined,
less costly, drug development process. We work closely with our
selected collaborators and leverage the combined expertise required
for science to advance.
Lead candidates from our portfolio are out-licensed or partnered
with investors through ValiRx subsidiary
companies for further clinical development and commercialisation. https://www.valirx.com/
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
About V Formation
V Formation is an established marketing and PR agency based at
BioCity Nottingham. The team of experienced marketing and PR
consultants deliver inspiring, insightful and supportive marketing
advice, strategy and tactics to take businesses closer to their
clients and help them find their competitive edge.
V Formation works with ambitious SMEs in the life sciences and
high-tech sectors, professional services firms and family
businesses. It provides in-house marketing and support, guidance on
strategic direction and assistance with tactical marketing and PR.
The company's directors are Sue Carr and Hilary Campton.
For more information: www.vformation.biz or 0115 822 6364
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBIGDIISBDGDL
(END) Dow Jones Newswires
August 17, 2022 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024